| [1] |
LI Junmin, NIU Hengli, XIE Mingquan, SU Jinlong.
Effects of hawthorn flavonoids on atherosclerotic and hyperlipidemia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 276-282.
|
| [2] |
LU Xiya, LI Yuxing, LI Wenzhi, PENG Yuanyuan, HU Yi, WAN Li, CHEN Bilian.
Analysis of prescribing of antiplatelet drug in patients with coronary heart disease in department of geriatrics
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1285-1291.
|
| [3] |
WANG Qi, ZOU Yunzeng.
New development of lipid-lowering therapy of coronary heart disease: Evinacumab
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 362-364.
|
| [4] |
WANG Qi, ZOU Yunzeng.
New development of lipid-lowering therapy of coronary heart disease: Inclisiran
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 365-368.
|
| [5] |
WANG Qi, ZOU Yunzeng.
New development of lipid-lowering therapy of coronary heart disease: Bempedoic acid
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 369-372.
|
| [6] |
CHANG Shufu .
Progress of medical treatment of coronary heart disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 405-408.
|
| [7] |
DENG Yifan, HE Shenghu, WANG Daxin, DAI Chengye, XU Xiaoting, ZHANG Jing.
Clinical study of effect of ezetimibe combined with statins on residual lipoprotein cholesterol and MACE events in patients undergoing emergency intervention with acute coronary syndrome
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1048-1052.
|
| [8] |
YANG Ming, DONG Xiaowen, HONG Huashan.
Statins for primary prevention of atherosclerotic cardiovascular disease in people 75 years of age and older
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1074-1080.
|
| [9] |
CHEN Miao, ZHANG Xinjin, MENG Hongli, YANG Bei, SONG Lijuan, ZOU Chuannan, GUAN Yingxia.
Therapeutic effect of bisoprolol combined with salvianolate on patients with coronary heart disease after PCI
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 451-457.
|
| [10] |
WANG Xiaqin， HE Fei, WANG Tong, HU Zhangle.
Admission Neutrophil-to-lymphocyte ratio predicts coronary lesion complexity and clinical risk in patients with unstable angina pectoris
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 296-300.
|
| [11] |
ZHANG Qian, FU Hong, CHEN Jinjin, ZHU Yubing.
Research progress of IL33/ST2 in acute coronary syndrome
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 1075-1080.
|
| [12] |
SHENG Yang, ZHANG Tianjie.
Effects of trimetazidine on serum-homocysteine and serum-gamma-glutamyl transferase level in the cases of stable angina cordis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 922-926.
|
| [13] |
PENG Qiuju, YAN Huacheng, SHI Lei.
Advances in the relationship between cytochrome P450 SNP and susceptibility to coronary heart disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 477-480.
|
| [14] |
WANG Weiyu, YU Hao.
Effects of gray drugs in patients with coronary heart disease: A network Meta-analysis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 301-307.
|
| [15] |
WANG Shiqi, HU Huawen, CHEN Xiaomin, WANG Jian, YE Honghua.
Effects of different intensities of warfarin on patients with coronary atherosclerotic heart disease complicated with atrial fibrillation: a comparative study
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1410-1414.
|
